Ratings by Barclays (Eliana Merle)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/14/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/7/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/5/2026 | uniQure BV | QURE | Downgrade | Equalweight (Overweight) |
23.46 (21.78) |
-7.16% | Details | |
| 9/30/2026 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 9/21/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2026 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2026 | Sagimet Biosciences Inc | SGMT | Upgrade | Overweight (Equalweight) |
10.94 (8.02) |
-26.69% | Details | |
| 9/4/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/25/2026 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/17/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/14/2026 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/14/2026 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2026 | MBX Biosciences Inc | MBX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2026 | Regenxbio Inc. | RGNX | Downgrade | Equalweight (Overweight) |
10.50 (6.93) |
-34% | Details | |
| 8/7/2026 | Regenxbio Inc. | RGNX | Downgrade | Equalweight (Overweight) |
10.50 (10.50) |
0% | Details | |
| 8/6/2026 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2026 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/3/2026 | Madrigal Pharmaceuticals | MDGL | Maintain | Overweight (N/A) |
|
Details | ||
| 8/3/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 7/31/2026 | Madrigal Pharmaceuticals | MDGL | Maintain | Overweight (N/A) |
|
Details | ||
| 7/30/2026 | uniQure BV | QURE | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2026 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 6/24/2026 | SAB Biotherapeutics | SABS | New Coverage | Overweight (N/A) |
3.87 (2.53) |
-34.63% | Details | |
| 6/22/2026 | uniQure BV | QURE | Upgrade | Overweight (Equalweight) |
46.29 (23.46) |
-49.32% | Details | |
| 6/18/2026 | uniQure BV | QURE | Upgrade | Overweight (Equalweight) |
48.16 (21.78) |
-54.78% | Details | |
| 6/17/2026 | uniQure BV | QURE | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/19/2026 | Gossamer Bio Inc. | GOSS | Maintain | Underweight (N/A) |
|
Details | ||
| 5/15/2026 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2026 | MBX Biosciences Inc | MBX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2026 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2026 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/30/2026 | Regeneron Pharma | REGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/30/2026 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 4/29/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/28/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 4/8/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 4/2/2026 | Moderna | MRNA | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/1/2026 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 3/31/2026 | Apellis Pharmaceuticals | APLS | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/25/2026 | Sarepta Therapeutics | SRPT | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/25/2026 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/23/2026 | uniQure BV | QURE | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/10/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2026 | Regeneron Pharma | REGN | New Coverage | Overweight (N/A) |
787.50 (790.74) |
0.41% | Details | |
| 3/3/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2026 | Gossamer Bio Inc. | GOSS | Downgrade | Underweight (Overweight) |
2.13 (8.77) |
311.74% | Details | |
| 2/23/2026 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/17/2026 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/28/2026 | Tyra Biosciences | TYRA | New Coverage | Overweight (N/A) |
30.17 (18.52) |
-38.61% | Details | |
| 1/28/2026 | MBX Biosciences Inc | MBX | New Coverage | Overweight (N/A) |
36.60 (49.61) |
35.55% | Details | |
| 1/28/2026 | Regenxbio Inc. | RGNX | New Coverage | Overweight (N/A) |
13.85 (10.50) |
-24.19% | Details | |
| 1/28/2026 | uniQure BV | QURE | New Coverage | Equalweight (N/A) |
25.27 (48.16) |
90.58% | Details | |
| 1/28/2026 | Sarepta Therapeutics | SRPT | New Coverage | Equalweight (N/A) |
22.80 (17.10) |
-25% | Details | |
| 1/28/2026 | Moderna | MRNA | New Coverage | Equalweight (N/A) |
47.99 (218.01) |
354.28% | Details | |
| 1/28/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 1/28/2026 | Sagimet Biosciences Inc | SGMT | New Coverage | Equalweight (N/A) |
6.03 (10.94) |
81.43% | Details | |
| 1/28/2026 | Kymera Therapeutics | KYMR | New Coverage | Overweight (N/A) |
71.06 (104.78) |
47.45% | Details | |
| 1/28/2026 | BridgeBio Pharma | BBIO | New Coverage | Overweight (N/A) |
77.81 (66.39) |
-14.68% | Details | |
| 1/28/2026 | Ionis Pharmaceuticals | IONS | New Coverage | Overweight (N/A) |
81.00 (42.94) |
-46.99% | Details | |
| 1/28/2026 | Apellis Pharmaceuticals | APLS | New Coverage | Equalweight (N/A) |
21.99 (41.03) |
86.58% | Details | |
| 1/28/2026 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Overweight (N/A) |
56.78 (54.68) |
-3.7% | Details | |
| 1/28/2026 | 4D Molecular Therapeutics | FDMT | New Coverage | Overweight (N/A) |
7.97 (12.14) |
52.32% | Details | |
| 1/28/2026 | Gossamer Bio Inc. | GOSS | New Coverage | Overweight (N/A) |
2.66 (2.13) |
-19.92% | Details | |
| 1/28/2026 | Ascendis Pharma | ASND | New Coverage | Overweight (N/A) |
233.65 (225.25) |
-3.6% | Details | |
| 1/28/2026 | Alnylam Pharmaceuticals | ALNY | New Coverage | Overweight (N/A) |
361.35 (231.83) |
-35.84% | Details | |
| 1/28/2026 | Insmed | INSM | New Coverage | Overweight (N/A) |
159.72 (96.27) |
-39.73% | Details | |
| 1/28/2026 | Inventiva SA | IVA | New Coverage | Overweight (N/A) |
7.07 (2.94) |
-58.42% | Details | |
| 1/28/2026 | Madrigal Pharmaceuticals | MDGL | New Coverage | Overweight (N/A) |
499.17 (449.74) |
-9.9% | Details | |
| 1/28/2026 | Altimmune | ALT | New Coverage | Overweight (N/A) |
5.66 (2.20) |
-61.13% | Details | |
| 1/28/2026 | PTC Therapeutics | PTCT | New Coverage | Overweight (N/A) |
76.23 (59.24) |
-22.29% | Details | |
| 1/28/2026 | Vertex | VRTX | New Coverage | Overweight (N/A) |
476.84 (499.74) |
4.8% | Details |
